Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
1-1-2020

CRI iAtlas: an interactive portal for immuno-oncology research.
James A Eddy
Vésteinn Thorsson
Institute for Systems Biology, Seattle, WA 98109, USA.

Andrew E Lamb
David L Gibbs
Institute for Systems Biology, Seattle, Washington.

Carolina Heimann
Institute for Systems Biology, Seattle, WA, 98109, USA.

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Genetics and Genomics Commons, and the Oncology Commons

Recommended Citation
Eddy, James A; Thorsson, Vésteinn; Lamb, Andrew E; Gibbs, David L; Heimann, Carolina; Yu, Jia Xin;
Chung, Verena; Chae, Yooree; Dang, Kristen; Vincent, Benjamin G; Shmulevich, Ilya; and Guinney, Justin,
"CRI iAtlas: an interactive portal for immuno-oncology research." (2020). Articles, Abstracts, and Reports.
4005.
https://digitalcommons.psjhealth.org/publications/4005

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St.
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.

Authors
James A Eddy, Vésteinn Thorsson, Andrew E Lamb, David L Gibbs, Carolina Heimann, Jia Xin Yu, Verena
Chung, Yooree Chae, Kristen Dang, Benjamin G Vincent, Ilya Shmulevich, and Justin Guinney

This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/4005

F1000Research 2020, 9:1028 Last updated: 04 DEC 2020

SOFTWARE TOOL ARTICLE

CRI iAtlas: an interactive portal for immuno-oncology
research [version 1; peer review: 3 approved]
James A. Eddy 1, Vésteinn Thorsson2, Andrew E. Lamb1, David L. Gibbs2,
Carolina Heimann2, Jia Xin Yu3, Verena Chung 1, Yooree Chae1, Kristen Dang1,
Benjamin G. Vincent4, Ilya Shmulevich2, Justin Guinney1
1Sage Bionetworks, Seattle, WA, 98101, USA
2Institute for Systems Biology, Seattle, WA, 98109, USA
3Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, 10006, USA
4University of North Carolina, Chapel Hill, NC, 27599, USA

v1

First published: 24 Aug 2020, 9:1028
https://doi.org/10.12688/f1000research.25141.1

Open Peer Review

Latest published: 24 Aug 2020, 9:1028
https://doi.org/10.12688/f1000research.25141.1

Reviewer Status

Abstract
The Cancer Research Institute (CRI) iAtlas is an interactive web
platform for data exploration and discovery in the context of tumors
and their interactions with the immune microenvironment. iAtlas
allows researchers to study immune response characterizations and
patterns for individual tumor types, tumor subtypes, and immune
subtypes. iAtlas supports computation and visualization of
correlations and statistics among features related to the tumor
microenvironment, cell composition, immune expression signatures,
tumor mutation burden, cancer driver mutations, adaptive cell
clonality, patient survival, expression of key immunomodulators, and
tumor infiltrating lymphocyte (TIL) spatial maps. iAtlas was launched
to accompany the release of the TCGA PanCancer Atlas and has since
been expanded to include new capabilities such as (1) user-defined
loading of sample cohorts, (2) a tool for classifying expression data
into immune subtypes, and (3) integration of TIL mapping from digital
pathology images. We expect that the CRI iAtlas will accelerate
discovery and improve patient outcomes by providing researchers
access to standardized immunogenomics data to better understand
the tumor immune microenvironment and its impact on patient
responses to immunotherapy.
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Introduction
Immuno-oncology (IO) is one of the most promising areas of
cancer research, with IO-based treatments demonstrating high
efficacy within certain cancer types and subsets of patients1–4.
To broaden the utility of these therapies to more patients, fundamental research is required to improve our understanding of
tumor-immune interactions—allowing the next-generation
of therapeutics and treatment strategies to emerge4. Advances
in the IO field are impeded by the inaccessibility of IO study
data and results and lack of data standardization, limiting the
ability to easily compare results across studies. This has led to
the underutilization of existing data, unnecessary study duplication, and failure to achieve rapid consensus in the field5. With
the vast increase in the number and scope of IO projects
expected in the coming years combined with widespread adoption of genomics and other high dimensional technologies, these
problems will be compounded going forward.
We developed the Cancer Research Institute (CRI) iAtlas
portal (https://www.cri-iatlas.org) to integrate IO research data,
with the goal of providing an interactive, exploratory hub for
the IO research community. In doing so, we hope to improve the
accessibility and utility of critical resources generated from
IO studies. iAtlas is a set of analytic modules—hosted on the
web—for studying interactions between tumors and the immune
microenvironment. These modules allow researchers to explore
associations among a variety of immune characterizations
as well as with genomic and clinical phenotypes.
The initial release of iAtlas (April 5, 2018) provided a rich
resource to complement analysis results from The Cancer Genome
Atlas (TCGA) Research Network on the TCGA data set comprising over 10,000 tumor samples and 33 tumor types6 (“The
Immune Landscape of Cancer”; here referred to as “Immune
Landscape”). This study identified six immune subtypes that
span cancer tissue types and molecular subtypes, and found that
these subtypes differ by somatic aberrations, microenvironment,
and survival. Per-sample characterizations included total lymphocytic infiltrate (from DNA methylation as well as H&E imaging data), estimated cell type fractions, immune gene signature

expression, MHC/HLA type and expression, antigen presentation machinery, T cell and B cell receptor repertoire inference,
viral/microbial characterization, associations with pathway
disruption and activity, and other analysis results. The
Immune Landscape6 manuscript reported on the most novel and
potentially therapeutically salient statistical associations between
these immune subtypes and the results of the immune characterization. We have continued to develop and evolve the CRI iAtlas
application; here, we report the technical design and implementation of iAtlas up to and including the recently released
version 1.27. This version includes new features requested
by users including: (1) user-defined loading of sample cohorts,
(2) a tool for classifying expression data into immune subtypes,
and (3) integration of TIL mapping from digital pathology
images.

Methods
Implementation
iAtlas is a web-based application to enable data exploration
for clinicians, biologists, and informaticists. The inputs and
architecture of the application are described below.

Data
The iAtlas app uses structured data and outputs from the Immune
Landscape6 study and the TCGA PanCancer Atlas initiative8,
which harmonized TCGA data, ensuring uniform quality control and sample inclusion, batch effect detection, normalization
across platforms, combination mutation calling from multiple
centers, and robustly compiled clinical and outcome data. A key
source of iAtlas data is the table summarizing tumor-sample and
immune characterizations for 11,080 TCGA patient participants
of the TCGA, Table S1 of the Immune Landscape6 manuscript,
here termed the “PanImmune Feature Matrix”. Auxiliary data
were sourced from files available on this manuscript’s data page
at the NCI Genomic Data Commons, from the TCGA PanCancer
Atlas Data Mirror, and from the TCGA PanCancer Atlas working
space in Synapse (see Data availability). iAtlas data were formatted as data frames (tables) and stored as “feather” files (https://
github.com/wesm/feather) on the application server for fast
loading (Table 1).

Table 1. iAtlas data files.
Filename

Description

fmx_df.feather

All immune readout features/variables (11,080) across samples (139).

feature_df.feather

Additional annotations for a subset (104) features.

feature_method_df.feather

Annotation of methods (21) used to compute features.

im_direct_relationships.
feather

Annotation and source of immunomodulators genes (79).

im_expr_df.feather

Gene expression for immunomodulators genes (76) across samples (9,693).

im_potential_factors.
feather

Additional genes (97) that have potential to be involved in immune modulation.

io_target_annotations.
feather

Annotation of immuno-oncology target genes (405).

io_target_expr_df.feather

Gene expression for immuno-oncology target genes (401) across samples (9,693)

sample_group_df.feather

Annotation of the sample groups (137 - TCGA studies, TCGA cancer subtypes and
Immune Subtypes).
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Annotation and browsing of the PanImmune Feature
Matrix: iAtlas includes a Data Description page with details on
all variables presented in individual modules, with the ability for users to “drill down” on related groups of variables to
understand how values were derived. Variables are listed in a
text-searchable table containing the name of the variable, the
‘Variable Class’, the unit (if applicable), and whether the variable is numeric or categorical. A ‘Variable Class’ is the name of a
group of variables that are of similar type and are often the result
of one particular analysis. Clicking on a row exposes a list of
all variables in the ‘Variable Class’ and provides links to text
descriptions of the analysis methods used to generate the
variables.

R/Shiny architecture
iAtlas is powered by Shiny9 and makes extensive use of Shiny
Modules10 to organize code into composable units (Figure 1).
Each iAtlas Analysis module is designed as a Shiny module, allowing simple integration of new analytical functionality.
iAtlas uses the tidyverse11 family of R packages (e.g., dplyr12,
tidyr13, purrr14, stringr15, tibble16) as well as the wrapr17 package to assist with tidy evaluation. These functions power the
data transformations of internal tabular data that are then used to
create the interactive plots (i.e., with the plotly18 graphing
library) and data tables (via the DT19 wrapper to the DataTables
library) seen through the iAtlas modules. We also make heavy
use of the crosstalk20 package to enable event-driven updates

Figure 1. iAtlas architecture overview. (A) Structured data from immunogenomic analyses, including the Immune Landscape6 study and
expanding over time, are organized and stored as flat (i.e., feather) files within Synapse and made available alongside the application code
in GitHub. (B) Tabular data from feather files are read from disk into memory to drive all operations related to sample groupings, sample-level
immune characterizations (readouts), and more granular—and high dimensional—assay measurements. (C) The core application code is
built as a catalog of Shiny Modules, each of which encapsulates logic for data transformation and visualization related to a scientific theme
or assay type. (D) Analysis modules, tools, and data description views are hosted in a unified application on shinyapps.io; the layout and
connectivity between modules in the iAtlas Explorer space are managed by the shinydashboard21 library.
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to the application state. The core iAtlas application is hosted
on https://shinyapps.io.

Analysis modules
The main feature of the iAtlas interface is the iAtlas
Explorer (Figure 2, found under the EXPLORE tab), which provides several Analysis modules to explore and visualize results.
Each module supports a type of exploration, with interactive
views and controls to enhance and extend the results and analytics as initially described in the Immune Landscape6 study. The
layout of pages and sections within the iAtlas Explorer is driven
by the shinydashboard21 package.
Within each module in iAtlas, results are displayed relative to
Sample Groups, corresponding to defined study cohorts. Several Sample Groups options are pre-loaded in the tool: first,
TCGA tumor type (TCGA Study), which are the standard
TCGA tumor types collected and designated by the TCGA. Second, TCGA tumor subtypes (TCGA Subtype), a compendium
of further subdivision of TCGA studies into molecular
subtypes according to publications by the TCGA Research
Network22. Finally, a division of tumor samples into distinct
patterns of immune response in cancer (Immune Subtypes) is
provided6. The choice of Sample Groups is global across all
modules but can be updated at any time via the Select Sample
Groups element in the side menu. We also allow users to upload
custom-grouped samples and analyze those with iAtlas modules. The selection of a sample group defines the samples utilized
in all analysis modules. For convenience, group annotations
can be displayed in visualizations within each module.
 ample Group Overview: View summary information for
S
user-selected sample cohort groups. There are currently three
sections: Custom Groups, Group Key, and Group Overlap.
Respectively, these sections permit loading of user-defined
sample groups, review of detailed annotations of sample
groups in a table, and display of overlap between different
types of groupings in a mosaic plot.
 umor Microenvironment: Explore immune cell proportions
T
in sample groups with two sets of faceted bar charts, one for
overall cellular proportions (i.e., leukocyte, stromal, and tumor
fraction) and one for computed immune cell proportions
(e.g., monocytes, CD8+ T cells, naive B cells).
I mmune Feature Trends: Visualize how immune readouts
vary across sample groups. Violin or box plots show the distribution of individual values across samples in each group,
while heatmaps and scatter plots can be used to explore the
correlation between any pair of variables within each group.
 linical Outcomes: Quantify the relationship between immune
C
response and disease outcome, in terms of either overall
survival (OS) or progression free interval (PFI)23. Results are
displayed as Kaplan Meier plots as well as heat maps showing
the concordance index between variables and survival.
I mmunomodulators: Explore the expression of genes
coding for immunomodulating proteins6, which include
therapeutically important immune checkpoint proteins.
Immunomodulators are organized by grouping into three

categories: Gene Family (such as “TNF”, “MHC Class II”,
“Immunoglobulin”, or “CXC chemokine”), Super Category
(such as “Ligand”, “Receptor”, or “Antigen presentation”), and Immune Checkpoint (classified as “Inhibitory”
or “Stimulatory”). Violin and box plots are again used to
present distributions, and a table provides additional metadata
about immunomodulator genes.
 river Associations: Test and visualize associations
D
between mutations and IO-related response variables. In
the Immune Landscape6 study, we reported somatic driver
alterations that are correlated with increases or decreases
in overall immune cell content, or with the fraction of
individual immune cell types. These and other variables
can be selected to calculate the significance of relationships
in each sample group and view results in a volcano
plot.
 IL Maps: We used the results of a recently reported
T
method to assess which spatial regions of hematoxylin and
eosin (H&E) whole slide images show evidence of tumorinfiltrating lymphocytes (TILs)24. The method, which uses
deep learning, was applied to thousands of H&E slides of
the TCGA, allowing slides to be characterized in terms
of TIL density and patterns.
Integration with Landscape of IO Drug Target Development: CRI has compiled and published comprehensive
overviews describing ongoing immunotherapy drug trials, including targets, agents, and tumor sites and has made summaries
available in an online resource, the Immune-Oncology Landscape
(IO Landscape) (www.cancerresearch.org/IO-landscape)25–28.
The iAtlas and the IO Landscape resource have been interlinked, enabling researchers to more readily understand the
relationship between targeted proteins in IO therapy and the
behavior of those targets in tumor tissue.
I n IO Target Gene Expression Distributions, the distribution of gene expression values for the selected IO target,
by sample group, is displayed in violin plots. Clicking
on the expression distribution (violin plot) of a particular
sample group, a histogram of the values is displayed.
 he IO Target Annotations section provides a searchable
T
table with IO targets and associated annotations. In the
rightmost column, a link is provided to a view of the
IO Landscape page, the selected target is highlighted in
summary barcharts showing the number of agents and cancer
types being studied for that target.
In the opposite direction, clicking on targets in the barcharts in
the IO Landscape on CRI web pages brings up the target gene
expression in iAtlas.

Tools
iAtlas Tools are accessible via the TOOLS tab on the iAtlas
Portal. Modules in this space of the portal enable users to “bring
their own data” for processing through immunogenomic algorithms that drive some of the results presented in the Analysis
modules described above.
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Figure 2. iAtlas Explorer. A range of Analysis modules (blue boxes above) are available that span from clinical to molecular and imaging
data types. Within each module, interactive controls allow researchers to expand views, exposing underlying data and results. Settings
are available (green box above) to select the sample groupings (TCGA Study, Disease Subtype, or Immune Subtype) which then
propagate through modules.
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Immune Subtype Prediction: This tool performs classification
of RNA-seq data into one of six immune subtypes as described
in the Immune Landscape6 study. Using a new ensemble model
based on XGBoost29, researchers can upload their own data
for classification30. Each member of the ensemble was trained
on a random subset of previously reported immune subtypes6
and features (described below) based on gene expression data
from the TCGA PanCancer Atlas Initiative8. All code and
methods have been confirmed as reproducible. An R package is
available on GitHub (https://github.com/CRI-iAtlas/ImmuneSubtypeClassifier)30.
The submitted expression data—subsetted to the 485 genes
that comprised the 5 signatures that produced the immune
subtypes—are used to generate robust features of three types:
quartiles, binary gene-pairs, and signature-pairs. For example,
given a single sample, genes are binned into quartiles and given
a bin label (quartile features). Then, similar to the “Top Scoring
Pairs” classifier31, genes are paired, and given binary values
depending on whether (gi > gj) for two gene expression values,
gi and gj. Lastly, signature-pair features are calculated using
the five immune subtype signatures, where smn = ∑ij(gim > gjn)/k,
where gim is gene i from signature m, gjn is gene j from signature
n, and k is the number of gene pairs considered resulting
in a value between 0 and 1. The features are computed
independently for each sample, and do not require normalization
across samples. These features are given to a trained XGBoost
classifier which returns a probability of being in any of the
six subtypes. Lastly, a “best call” is made with a final trained
XGBoost classifier using the six probabilities as input. To validate the robustness of the classifier, TCGA data were processed
using four different software pipelines and normalization,
showing that classification performance was independent of the
gene expression quantification method30. Along with a downloadable table of results, visualizations are also provided. This
tool is a convenient way for researchers to apply the methods of the Immune Landscape6 study to their own data without
difficult statistical coding.

Operation
To use iAtlas, access the web app via https://www.cri-iatlas.org.
The software can also be run locally on all platforms (Windows,
Mac, Linux). To run the Shiny app locally, a working R installation with necessary libraries is required and an installation
of RStudio is recommended.
To install and run the app locally:
1. Clone shiny-iatlas GitHub repository
(git clone https://github.com/CRI-iAtlas/shiny-iatlas)
2.

Open shiny-iatlas.Rproj in RStudio

3.

Install packages. In the RStudio console, run:
renv::restore()

4.

Start the app by running:
shiny::runApp()

Use cases
Reproducing published results and gaining information on
underlying data
One of the initial motivations behind iAtlas was to provide
an interactive platform that is able to reproduce figures published
in the Immune Landscape6 manuscript but expands that with
the ability to generate variations of those figures, for other
choices of tumor samples and immune readouts of interest. As an
example, in order to reproduce Figure 4A from the Immune
Landscape6 publication, which shows the correlation of DNA
damage measures with the fraction of leukocytes in the
tumor, we began by selecting the EXPLORE tab. We then
opened the Immune Feature Trends module and selected the
“Immune Subtype” option under Select Sample Groups
in the Explorer Settings panel in the left menu. In the ensuing
module page, at the Correlations section (Figure 3), we selected
the “DNA Alterations” under Select or Search for
Variable Class, “Leukocyte Fraction” under Select or
Search for Response Variable, and the “Spearman” method
under Select or Search for Correlation Method
(each a separate dropdown menu). This produced a heatmap identical in content to Figure 4A in the Immune Landscape6 publication. However, the heatmap provides additional information on
underlying data via interactivity: by clicking on a heatmap-cell,
the underlying data is displayed in a scatterplot. Hovering a cursor
over a point in the scatter plot reveals sample-level information.
Table 2 lists the particular manuscript figures (from the Immune
Landscape6 publication) that can be reproduced or adapted
to specific research questions.

Exploring new IO results
With the iAtlas portal, scientists can explore and answer new
questions based on specific research interests. For example, we
asked: “What is the expression level of PD-L1, a therapeutically
important protein, in subtypes of breast cancer?” To answer this
question, from the landing page, we first selected the “TCGA
Subtype” sample group, followed by the “Breast Invasive
Carcinoma (BRCA)” study subset. Next, we selected the Immunomodulators module (Figure 4). Based on a very quick
scan of the drop down, we didn’t see any names that matched
our gene of interest, so we scrolled further down on the page to
view the table of ‘Immunomodulator Annotations’. By typing in
the first few letters of a gene name (e.g., “PD...”) into the ‘Search’
field, the table was filtered to a set of matching genes, and
we could see that “PD-L1” is the Friendly Name for the gene
“CD274” (the approved gene symbol on genenames.org). After
returning to the Select or Search for Variable drop
down menu above and selecting “CD274 (PD-L1)”, we
were able to see a display of violin plots showing the distributions of gene expression across BRCA molecular subtypes. We
could then visually compare distributions between subtypes,
noticing for example the elevated expression level in the Her2
subtype compared to Basal breast cancer. These comparisons
can guide further characterization not only of how gene expression can differ between TCGA subtypes of breast cancer, but
also how these subtype-specific differences might correlate with
clinical outcomes, as investigated in other studies32–34. Using
Page 7 of 16
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Figure 3. Visualization of the correlation of DNA damage in cancer with the degree of immune cell infiltration. Top right: Original
manuscript figure panel from the Immune Landscape6 study. Bottom left: Equivalent figure generated in iAtlas. By selecting a specific
heatmap cell (highlighted), the underlying data is displayed (Bottom right), using the selections shown. Individual points can be selected to
get sample IDs and additional information (blue box).

Figure 4. Visualization of the PD-L1 immunomodulator expression patterns in breast cancer subtypes. Selection for PD-L1 expression
distributions displayed as violin plots within molecular subtypes of breast cancer, according to “PAM-50” classification. Elevated expression
is seen in the HER2 subtype.

Table 2. Immune Landscape figures in iAtlas. iAtlas
Analysis module (Column 1) and examples of figure
panels (Column 2) in the Immune Landscape6 manuscript
that can be generated using the module. Researchers
can use this as a starting point for tailoring figures to their
own interests.
iAtlas Analysis module

Immune Landscape figures

Sample Group Overview

1D, S1B

Tumor Microenvironment

2A, 2C, S2A

Immune Feature Trends

1C, 2B, 4A

Clinical Outcomes

3A, 3B, 3C, S3A, S3B, S3C

Immunomodulators

6B

Driver Associations

4D

TIL Maps

2D
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this module and others, the researcher has the ability to answer
new questions which could lead to developments in oncology
research.

Classification of immune subtypes on new data
In order to classify any tumor-derived gene expression samples into immune subtypes6,30, users can select the TOOLS tab
(top right), which leads to an interface containing notes, several links and the controls. In order to classify new data, we
submitted data as a text file, in this case tab separated, with
the first column containing gene IDs and later columns containing samples. A provided example file can be found in the
description text. The first row of the data was a header containing sample IDs. Gene IDs can be either HGNC gene
symbols (preferred), Entrez ID, or Ensembl identifiers. The
locally available data was selected using the Browse button, and
the file delimiter was selected, along with gene ID type, using
drop down menus. Hitting the GO button produced classifications, signature scores, and cluster probabilities, which were
reported in a table that was downloaded as a csv, xlsx, or pdf file.
In addition, a barplot with the frequency of predicted subtypes
for the submitted data was displayed.
All data required to run the application and describe the Use
Cases are available in GitHub and archived with Zenodo7.

Conclusions
CRI iAtlas is a platform that facilitates analysis and exploration
of the tumor immune microenvironment by making IO-related
data and tools accessible to the research community. iAtlas
builds upon the comprehensive TCGA analysis of tumorimmune interactions on 10,000 tumors and illustrates how
commonalities and differences of the immune response across
33 tumor types can provide clues for advancing therapeutics.
iAtlas provides researchers with the tools to dive deeper into
immunogenomic and clinical data and to develop and refine
hypotheses regarding tumor-immune interactions that will
empower researchers to gain insight and design the next
generation of immuno-oncology treatment strategies.

Data availability
Source data
Original data files from the TCGA PanCancer Atlas publication
can be found in the NCI Genomic Data Commons (https://gdc.
cancer.gov/about-data/publications/panimmune) or the TCGA

PanCancer Atlas Data Mirror (https://isb-cancer-genomics-cloud.
readthedocs.io/en/latest/sections/PanCancer-Atlas-Mirror.html.

Extended data
Zenodo: CRI iAtlas (Version 1.2.0). https://doi.org/10.5281/
zenodo.39267577.
Folder ‘Data’ contains all data required to run the application
and describe Use Cases. This is also available on GitHub.
License: Apache License 2.0.

Software availability
Source code is available from GitHub: https://github.com/
CRI-iAtlas/shiny-iatlas.
Source code for the specific version described at the time of
publication: https://github.com/CRI-iAtlas/shiny-iatlas/releases/
tag/v1.2.0.
Archived source code at the time of publication: https://doi.
org/10.5281/zenodo.39267577.
Hosted iAtlas application on shinyapps.io: https://isb-cgc.shinyapps.io/shiny-iatlas.
Pinned version of the hosted iAtlas app described at the time
of publication: https://isb-cgc.shinyapps.io/iatlas_v1-2.
License: Apache License 2.0.
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Nathan E. Reticker-Flynn
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
In their manuscript, Eddy et al. describe the interactive data portal iAtlas that accompanies the
authors’ 2018 publication in Immunity, “The Immune Landscape of Cancer”. In that seminal paper,
the authors present a compendium of analyses they performed to interrogate the diversity of
immune states across human cancers using publicly available data from The Cancer Genome Atlas
(TCGA). While the Immunity manuscript described the identification and characterization of six
distinct “Immune Subtypes” and highlighted examples of key distinguishing features of the data
sets, the accompanying iAtlas tool enables users to explore these rich analyses on their own, using
parameters of their choosing. Comprising over 11,000 patients across 33 cancer types, these data
represent an exceptionally comprehensive patient cohort from which a wide range of
immunological insights can be gleaned.
iAtlas, which is available as both a web-based Shiny app and for offline implementation in R from
GitHub, is a remarkably powerful and user-friendly portal through which researchers can easily
interrogate the TCGA datasets for all of the immune analyses presented in their manuscript. The
platform allows users to group their analyses by examining differences across TCGA cancer types,
tumor subtypes (e.g. Luminal A vs. Her2 breast cancers), or their six defined Immune Subtypes.
Furthermore, they have included the ability for users to define their own subsets and perform all
of the included analyses across these subsets. The analyses within iAtlas include cellular readouts
(e.g. degree of immune infiltration, fractions of particular leukocyte populations), molecular
readouts (e.g. proliferation rates, gene expression, SNVs, CNAs, etc.), lymphocyte receptor
(TCR/BCR) repertoires, network analyses, and tissue-level analyses (e.g. architectural
characteristics). These variables can be investigated in the context of a wide range of parameters
(e.g. clinical outcomes, correlations to driver gene mutations, etc.), designated as distinct modules,
rendering the tool incredibly powerful with a near limitless number of potential questions to
investigate in the field of tumor immunology. iAtlas is a remarkable tool with an extremely rich
associated dataset whose elegant and straight-forward implementation render it accessible to
researchers of all computational abilities.
I have no major concerns with this manuscript. What follows are a list of comments, minor
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concerns, and suggestions that should not preclude acceptance of the manuscript but rather
serve as potential items to include in future releases of iAtlas:
1. In the Cell Type Fractions of the Tumor Microenvironment module, it would be helpful to
include an option for the user to select which CIBERSORT immune types to include as a
custom “Cell Fraction Type”. For example, a user could select only memory resting CD4 T
cells, memory activated CD4 T cells, naïve CD4 T cells, Tregs, and Tfh if they wanted to easily
visualize the relative fractions of particular Th subsets within the CD4 compartment across
groups. In some instances, it may be more biologically meaningful to compare these shifts
within broad subsets without having to account for changes in unrelated populations (e.g.
M2 macrophages).
2. In the Tumor Microenvironment module, when comparing leukocyte fraction to the total
stromal fraction, there are typically a small number of samples where the leukocyte fraction
exceeds the total stromal fraction, denoted as “estimation artifacts”. What is the source of
these artifacts? It may help to include a description of this in the legend.
3. As a general comment, in a variety of instances it might be informative if there would be a
way to include statistics between groups, though I recognize that doing so could be
computationally intensive and invalid in many instances. Nonetheless, given the large
sample sizes I am often left wondering if modest differences between groups are
statistically meaningful and where inferences can be drawn (e.g. an increase in Treg fraction
from 0.024 in the “Inflammatory” subtype to 0.029 in the “TGF-b Dominant” subtype).
4. The Data Description tab might be aided by including a sentence or phrase within the table
stating what each variable is without requiring following all of the methods links. For
example, I am assuming the BCR/TCR Shannon incorporates both the richness and
evenness to depict the diversity of the repertoire, but it might be helpful to state the
meaning of the terms in the table.
5. For the Clinical Outcomes, it might be useful to include “Immune Subtypes” as a variable
when analyzing TCGA Study so that users can evaluate the survival probabilities depending
on immune subtype for a given cancer.
6. There appears to be a minor issue wherein no results can be displayed for the Concordance
Index of the Clinical Outcomes analyses for most, if not all, variables when using TCGA
Study for the Sample Groups.
7. The TIL Maps module is quite impressive and the ability to examine the histology from each
of the patients along with the calculated metrics is an outstanding feature. Nonetheless,
when one clicks one of the violin plots, the annotation lists seems only to display an
individual patient rather than the entire list of patients for that group.
8. The Immune association with driver gene analysis is a powerful tool whose insights have
far-reaching implications and represent an active area of research in tumor immunology.
While the interactive volcano plot is highly informative and useful for identifying genes of
interest, it would also be useful to be able to run the analysis in the opposite direction. If
possible, it would be informative to be able to select a driver gene and see where it lies in
the various volcano plots and which of the variables are correlated with the mutation.
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Is the rationale for developing the new software tool clearly explained?
Yes
Is the description of the software tool technically sound?
Yes
Are sufficient details of the code, methods and analysis (if applicable) provided to allow
replication of the software development and its use by others?
Yes
Is sufficient information provided to allow interpretation of the expected output datasets
and any results generated using the tool?
Yes
Are the conclusions about the tool and its performance adequately supported by the
findings presented in the article?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Tumor immunology, systems biology, immunotherapy, models of cancer,
metastasis
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
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Australia
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This article presents CRI iAtlas, a website with a suite of interactive tools for exploring and
visualizing tumor immune microenvironment data collected by The Cancer Genome Atlas project.
It is based on robust, well-established R packages that are widely used for filtering, analysing and
displaying large, multi-faceted data sets of the type used here.
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The design and implementation of the website are well described and the underlying code and
data provided in readily accessible public repositories.
CRI iAtlas will provide a valuable resource for the cancer immunology field. The tools it provides
will enable a range of users to quickly and easily access and visualize complex genomics and
immunology data sets. The interface is user friendly and well documented, particularly for those
without bioinformatics training.
The detailed instructions certainly made it easier to understand what each tool did the first time I
tried to use them. However, they also kind of clutter the interface. It would be nice to be able
minimize those panels without minimizing the entire module.
It would also be helpful to search the Driver Associations data for interactions involving certain
genes of interest instead of having to scan through the volcano plots point by point.
But those are minor quibbles. Overall this is a slick and powerful online tool that will be welcomed
by the field.
Is the rationale for developing the new software tool clearly explained?
Yes
Is the description of the software tool technically sound?
Yes
Are sufficient details of the code, methods and analysis (if applicable) provided to allow
replication of the software development and its use by others?
Yes
Is sufficient information provided to allow interpretation of the expected output datasets
and any results generated using the tool?
Yes
Are the conclusions about the tool and its performance adequately supported by the
findings presented in the article?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Cancer Genomics, Bioinformatics
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
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Vincent Rouilly
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In this article, the authors introduce iAtlas, a web-based application that allows to browse a rich
diversity of immune profiles, generated from the public TCGA dataset, and published in the
landmark Immune Landscape study.
Further than simply giving the possibility to replicate the published figures, the application
provides a great flexibility to explore the entire PanImmune feature matrix through sophisticated
and interactive tools.
The modular architecture and the features of the software are clearly explained. Detailed
instructions are provided. And, all the necessary information is given to run the application.
Its source code repository on github is well structured. The documentation is very comprehensive,
as it gives ample information on the underlying methods, as well as how to extend the software
application.
It is a very valuable resource for the Immuno-oncology community.
Is the rationale for developing the new software tool clearly explained?
Yes
Is the description of the software tool technically sound?
Yes
Are sufficient details of the code, methods and analysis (if applicable) provided to allow
replication of the software development and its use by others?
Yes
Is sufficient information provided to allow interpretation of the expected output datasets
and any results generated using the tool?
Yes
Are the conclusions about the tool and its performance adequately supported by the
findings presented in the article?
Yes
Competing Interests: No competing interests were disclosed.
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I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
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